Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951360 | 0.88 | PPM1D (0.33) | PPM1D | |
| SCHEMBL16622537 | 0.87 | PPM1D (0.33) | PPM1D | |
| SCHEMBL15115980 | 0.84 | PPM1D (0.37) | PPM1DDGAT1 | |
| SCHEMBL15227908 | 0.84 | PPM1D (0.37) | PPM1DDGAT1 | |
| SCHEMBL8042085 | 0.83 | PPM1D (0.30) | PPM1DDGAT1 | |
| SCHEMBL8041329 | 0.77 | CYP4F2 (0.40) | PPM1DDGAT1 | |
| SCHEMBL15111450 | 0.76 | PPM1D (0.36) | PPM1D | |
| SCHEMBL22079855 | 0.76 | PPM1D (0.34) | PPM1D | |
| SCHEMBL15241935 | 0.76 | PPM1D (0.36) | PPM1D | |
| SCHEMBL15237366 | 0.76 | CYP4F2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9492496-B2 | Aminothiazoles and their uses | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| WO-2009074605-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | ABAT, AADAT, AADAC | PPM1D 4104/4885DGAT1 976/4885 |
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, BCAT2 | PPM1D 2491/4885DGAT1 1850/4885 |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, BCAT2 | PPM1D 2491/4885DGAT1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.